FEATURED CONTRIBUTED CONTENT
In this episode, Pete Belden talks about the role of third-party logistics in the commercialization process, how manufactures should solve challenges using 3PL partners, and where 3PL services are headed in the future.
GSK’s move to a new model of customer engagement has generated a great deal of debate. Indeed, many commentators remain skeptical that this ‘ethical’ model – especially the decoupling of sales incentives from prescription volume isn’t robust enough to deliver results in the long-term. A myriad of questions is being asked by onlookers: How does […]
Dr. Perry discusses the complexities of self-management across chronic disease. We explore the application of health psychology and the role of technology in helping pharma support patients to stay on track with their prescribed treatment.
The Healthcare Businesswomen’s Association’s refreshed mission and subsequent strategic plan has been in place throughout 2016. As we move toward our goal of gender parity through gender partnership, we can look to current research to see where we are. We are working toward gender parity in leadership positions. We are partnering with organizations and companies that have parallel missions and vision. We are […]
This paper discusses one of the potentially more impactful new dynamics in the pricing of pharmaceuticals—the advent of indication-specific pricing. Our goal is to provide context to this important change, highlight some of the implications about which biopharma companies should be aware, and leave you with a framework for raising and addressing pertinent questions across […]
Recently, Chiltern sponsored a white paper and podcast on a very interesting topic. It concerns developing mobile medical apps for medical devices. Integrating any set of technologies can be difficult. A couple months ago I struggled trying to get a new TV working with an existing home theater system, blu-ray player, cable box DVR, and a universal […]
There’s a population tsunami approaching: the coming of age of the Gen X and Millennial generations. And it’s fueling the rise of the new Patient Economy. These generations account for about 50% of the U.S. population, and they are a powerful force for change. In the new Patient Economy, how each generation consumes healthcare and […]
To be successful in developing a pharmaceutical asset you have to identify the need and define the commercial value early on in the development process, as well as revisiting and refining the value as you progress through the various phases of development. This means understanding what else is coming onto the market from a competitive […]
Exciting advances in science have led to developing treatment breakthroughs—such as gene scripting therapies—that could represent the first potential cures for rare diseases and other life-threatening conditions. Gene therapies offer dramatic promise—but also come with high costs. When viewing gene therapies and other expensive treatment options against the backdrop of an evolving healthcare landscape, several […]
Maintenance of Mature and Generic Products: A Pragmatic Approach to Successfully Navigating the Safety and Regulatory Continuum
While development of promising new products is an obvious area of focus for biopharmaceutical companies, maintenance of already established marketed products is a critical activity that cannot be ignored. As products mature, there is high pressure to grow or sustain revenue from established products whilst keeping maintenance costs low. Creating an environment where information from […]
The self-management challenges for people living with chronic conditions are broad and are influenced by a range of factors, both internal and external to the individual. This report outlines how when designing support systems and programs to aid self-management, it is important to consider the individual and the context within which the behavior will occur.